Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H26ClN |
Molecular Weight | 279.848 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CC(N(C)C)C1(CCC1)C2=CC=C(Cl)C=C2
InChI
InChIKey=UNAANXDKBXWMLN-UHFFFAOYSA-N
InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
Molecular Formula | C17H26ClN |
Molecular Weight | 279.848 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm
Curator's Comment: description was created based on several sources, including http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm
Subitramine is a potent inhibitor of monoamines (serotonin, dopamine, noradrenaline) reuptake that was approved by FDA for the treatmen of obesity. Sibutramine is metabolized to metabolites M1 and M2 which are more active toward the monoamine transporters.The drug was withdrawn from the market because of clinical trial data indicating an increased risk of heart attack and stroke. It was sold under a variety of brand names including Reductil, Meridia and Sibutrex.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P31645 Gene ID: 6532.0 Gene Symbol: SLC6A4 Target Organism: Homo sapiens (Human) |
298.0 nM [Ki] | ||
Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) |
943.0 nM [Ki] | ||
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) |
5451.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MERIDIA Approved UseMERIDIA is indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.12 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15823773/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4067.7 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
6.4 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15823773/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6579.8 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4368.5 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
SIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25.5 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
133.03 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15823773/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
100736.1 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
92.1 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
205.86 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15823773/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
194500.9 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
23296.9 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
SIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.31 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15823773/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
25.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
17.2 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
23.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15823773/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
23.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
3.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29403750/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
SIBUTRAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIDESMETHYLSIBUTRAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: 14 |
unhealthy, adult n = 2068 Health Status: unhealthy Condition: obesity Age Group: adult Sex: unknown Population Size: 2068 Sources: Page: 14 |
Disc. AE: Hypertension, Tachycardia... AEs leading to discontinuation/dose reduction: Hypertension (0.4%) Sources: Page: 14Tachycardia (0.4%) |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Disc. AE: Palpitations... Other AEs: Palpitations... AEs leading to discontinuation/dose reduction: Palpitations (1 patient) Other AEs:Palpitations (2 patients) Sources: |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Other AEs: Palpitations, Paresthesia... Other AEs: Palpitations (1 patient) Sources: Paresthesia (1 patient) Anxiety (1 patient) Insomnia (1 patient) Fatigue (1 patient) |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Disc. AE: Hypertension, Tachycardia... Other AEs: Dry mouth, Anorexia... AEs leading to discontinuation/dose reduction: Hypertension (<1.4%) Other AEs:Tachycardia (<3%) Dry mouth (32.2%) Sources: Anorexia (32.2%) Insomnia (10.3%) Increased appetite (11.6%) Nausea (8.2%) Dyspepsia (5.5%) Nervousness (12.3%) Asthenia (8.9%) Dizziness (12.3%) Constipation (12.3%) Rash (4.1%) Palpitation (4.1%) Vasodilation (4.8%) Dyspnea (1.4%) Taste perversion (4.1%) Hypertension (1.4%) Sweating (4.1%) Tachycardia (6.8%) Ecchymosis (1.4%) Paresthesia (3.4%) |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Disc. AE: Hypertension, Tachycardia... Other AEs: Dry mouth, Anorexia... AEs leading to discontinuation/dose reduction: Hypertension (<2%) Other AEs:Tachycardia (<3%) Dry mouth (16.7%) Sources: Anorexia (18.7%) Insomnia (9.4%) Increased appetite (16.7%) Nausea (3.4%) Dyspepsia (4.4%) Nervousness (6.4%) Asthenia (7.9%) Dizziness (7.9%) Constipation (10.8%) Rash (4.9%) Palpitation (4.9%) Vasodilation (2%) Dyspnea (1.5%) Taste perversion (2%) Hypertension (4.9%) Sweating (1%) Tachycardia (4.4%) Ecchymosis (0.5%) Paresthesia (3.9%) |
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Disc. AE: Hypertension, Tachycardia... Other AEs: Dry mouth, Anorexia... AEs leading to discontinuation/dose reduction: Hypertension (2%) Other AEs:Tachycardia (3%) Dry mouth (31.8%) Sources: Anorexia (31.8%) Insomnia (24.5%) Increased appetite (21.2%) Nausea (12.6%) Dyspepsia (12.6%) Nervousness (11.3%) Asthenia (10.6%) Dizziness (7.9%) Constipation (7.9%) Rash (7.3%) Palpitation (6%) Vasodilation (5.3%) Dyspnea (4.6%) Taste perversion (4.6%) Hypertension (3.3%) Sweating (2.6%) Tachycardia (2.6%) Ecchymosis (2%) Paresthesia (1.3%) |
5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Disc. AE: Hypertension, Tachycardia... Other AEs: Dry mouth, Anorexia... AEs leading to discontinuation/dose reduction: Hypertension (<1.2%) Other AEs:Tachycardia (<1.8%) Dry mouth (11.8%) Sources: Anorexia (18.9%) Insomnia (8.3%) Increased appetite (16.6%) Nausea (4.1%) Dyspepsia (4.1%) Nervousness (5.3%) Asthenia (7.1%) Dizziness (8.9%) Constipation (13%) Rash (4.1%) Vasodilation (2.4%) Dyspnea (0.6%) Taste perversion (1.2%) Hypertension (1.2%) Sweating (1.2%) Tachycardia (1.8%) Ecchymosis (1.2%) Paresthesia (2.4%) |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Disc. AE: Hypertension, Tachycardia... Other AEs: Dizziness, Dry mouth... AEs leading to discontinuation/dose reduction: Hypertension (<2%) Other AEs:Tachycardia (<3%) Dizziness (8.2%) Sources: Dry mouth (25.5%) Anorexia (21.4%) Insomnia (10.2%) Increased appetite (14.3%) Nausea (5.1%) Dyspepsia (8.2%) Nervousness (7.7%) Asthenia (6.1%) Constipation (11.7%) Rash (7.1%) Palpitation (2.6%) Vasodilation (2%) Dyspnea (1%) Taste perversion (2.6%) Hypertension (5.1%) Sweating (2.6%) Tachycardia (7.7%) Ecchymosis (3.1%) Paresthesia (2%) |
1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Disc. AE: Hypertension, Tachycardia... Other AEs: Dry mouth, Anorexia... AEs leading to discontinuation/dose reduction: Hypertension (<2%) Other AEs:Tachycardia (<0.7%) Dry mouth (6%) Sources: Anorexia (20.1%) Insomnia (12.1%) Increased appetite (11.4%) Nausea (3.4%) Dyspepsia (4%) Nervousness (4.7%) Asthenia (2.7%) Dizziness (4.7%) Constipation (6.7%) Rash (5.4%) Palpitations (2%) Vasodilation (1.3%) Dyspnea (1.3%) Taste perversion (0.7%) Hypertension (2%) Tachycardia (0.7%) Paresthesia (2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | 0.4% Disc. AE |
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: 14 |
unhealthy, adult n = 2068 Health Status: unhealthy Condition: obesity Age Group: adult Sex: unknown Population Size: 2068 Sources: Page: 14 |
Tachycardia | 0.4% Disc. AE |
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: 14 |
unhealthy, adult n = 2068 Health Status: unhealthy Condition: obesity Age Group: adult Sex: unknown Population Size: 2068 Sources: Page: 14 |
Palpitations | 1 patient Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Palpitations | 2 patients | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Anxiety | 1 patient | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Fatigue | 1 patient | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Insomnia | 1 patient | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Palpitations | 1 patient | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Paresthesia | 1 patient | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 32 years n = 7 Health Status: unhealthy Condition: vasovagal syncope Age Group: mean 32 years Sex: M+F Population Size: 7 Sources: |
Dyspnea | 1.4% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Ecchymosis | 1.4% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Hypertension | 1.4% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Insomnia | 10.3% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Increased appetite | 11.6% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Constipation | 12.3% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Dizziness | 12.3% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Nervousness | 12.3% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Paresthesia | 3.4% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Anorexia | 32.2% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Dry mouth | 32.2% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Palpitation | 4.1% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Rash | 4.1% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Sweating | 4.1% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Taste perversion | 4.1% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Vasodilation | 4.8% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Dyspepsia | 5.5% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Tachycardia | 6.8% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Nausea | 8.2% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Asthenia | 8.9% | 20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Hypertension | <1.4% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Tachycardia | <3% Disc. AE |
20 mg 1 times / day multiple, oral Studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, mean 42.9 years n = 146 Health Status: unhealthy Condition: obesity Age Group: mean 42.9 years Sex: M+F Population Size: 146 Sources: |
Ecchymosis | 0.5% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Sweating | 1% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Dyspnea | 1.5% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Constipation | 10.8% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Dry mouth | 16.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Increased appetite | 16.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Anorexia | 18.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Taste perversion | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Vasodilation | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Nausea | 3.4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Paresthesia | 3.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Dyspepsia | 4.4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Tachycardia | 4.4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Hypertension | 4.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Palpitation | 4.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Rash | 4.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Nervousness | 6.4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Asthenia | 7.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Dizziness | 7.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Insomnia | 9.4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Hypertension | <2% Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Tachycardia | <3% Disc. AE |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, mean 43.3 years n = 203 Health Status: unhealthy Condition: obesity Age Group: mean 43.3 years Sex: M+F Population Size: 203 Sources: |
Paresthesia | 1.3% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Asthenia | 10.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Nervousness | 11.3% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Dyspepsia | 12.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Nausea | 12.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Ecchymosis | 2% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Hypertension | 2% Disc. AE |
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Sweating | 2.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Tachycardia | 2.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Increased appetite | 21.2% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Insomnia | 24.5% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Tachycardia | 3% Disc. AE |
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Hypertension | 3.3% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Anorexia | 31.8% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Dry mouth | 31.8% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Dyspnea | 4.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Taste perversion | 4.6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Vasodilation | 5.3% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Palpitation | 6% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Rash | 7.3% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Constipation | 7.9% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Dizziness | 7.9% | 30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 151 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 151 Sources: |
Dyspnea | 0.6% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Ecchymosis | 1.2% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Hypertension | 1.2% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Sweating | 1.2% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Taste perversion | 1.2% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Tachycardia | 1.8% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Dry mouth | 11.8% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Constipation | 13% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Increased appetite | 16.6% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Anorexia | 18.9% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Paresthesia | 2.4% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Vasodilation | 2.4% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Dyspepsia | 4.1% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Nausea | 4.1% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Rash | 4.1% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Nervousness | 5.3% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Asthenia | 7.1% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Insomnia | 8.3% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Dizziness | 8.9% | 5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Hypertension | <1.2% Disc. AE |
5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Tachycardia | <1.8% Disc. AE |
5 mg 1 times / day multiple, oral Minumum effective dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, mean 43.4 years n = 169 Health Status: unhealthy Condition: obesity Age Group: mean 43.4 years Sex: M+F Population Size: 169 Sources: |
Dyspnea | 1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Insomnia | 10.2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Constipation | 11.7% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Increased appetite | 14.3% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Paresthesia | 2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Vasodilation | 2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Palpitation | 2.6% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Sweating | 2.6% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Taste perversion | 2.6% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Anorexia | 21.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Dry mouth | 25.5% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Ecchymosis | 3.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Hypertension | 5.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Nausea | 5.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Asthenia | 6.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Rash | 7.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Nervousness | 7.7% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Tachycardia | 7.7% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Dizziness | 8.2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Dyspepsia | 8.2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Hypertension | <2% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Tachycardia | <3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, mean 44.2 years n = 196 Health Status: unhealthy Condition: obesity Age Group: mean 44.2 years Sex: M+F Population Size: 196 Sources: |
Tachycardia | 0.7% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Taste perversion | 0.7% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Dyspnea | 1.3% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Vasodilation | 1.3% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Increased appetite | 11.4% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Insomnia | 12.1% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Hypertension | 2% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Palpitations | 2% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Paresthesia | 2% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Asthenia | 2.7% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Anorexia | 20.1% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Nausea | 3.4% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Dyspepsia | 4% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Dizziness | 4.7% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Nervousness | 4.7% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Rash | 5.4% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Dry mouth | 6% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Constipation | 6.7% | 1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Tachycardia | <0.7% Disc. AE |
1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Hypertension | <2% Disc. AE |
1 mg 1 times / day multiple, oral Minumum effective dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy, mean 44.5 years n = 149 Health Status: unhealthy Condition: obesity Age Group: mean 44.5 years Sex: M+F Population Size: 149 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 0.829 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 15.6 uM] | |||
yes [IC50 29 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/23777987/ Page: 5.0 |
yes [IC50 >50 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18474675/ Page: 5.0 |
yes | |||
Page: 3.0 |
yes | yes (co-administration study) Comment: Ketoconazole: resulted in moderate increases in AUC and Cmax of 58% and 36% for M1 and of 20% and 19% for M2, respectively; Erythromycin: resulted in small increases in the AUC (less than 14%) for M1 and M2. A small reduction in Cmax for M1 (11%) and a slight increase in Cmax for M2 (10%) were observed. Other tested drugs that are substrates and/or inhibitors of CYP 450 isozymes were tested. Cimetidine: resulted insmall increases in combined (M1 and M2) plasma Cmax (3.4%) and AUC (7.3%); Simvastatin: no significant effect on plasma Cmax and AUC of M2 or M1 and M2 combined. The Cmax (16%) and AUC (12%) of M1 were slightly decreased. Simvastatin slightly decreased sibutramine Cmax (14%) and AUC (21%); Omeprazole: slightly increased plasma Cmax and AUC of M1 and M2 combined (approximately 15%). M2 Cmax and AUC were not significantly affected whereas M1 Cmax (30%) and AUC (40%) were modestly increased. Plasma Cmax (57%) and AUC (67%) of unchanged sibutramine were moderately increased; Olanzapine: Olanzapine had no significant effect on plasma Cmax and AUC of M2 and M1 and M2 combined, or the AUC of M1; Lorazepam: Lorazepam had no significant effect on the pharmacokinetics of sibutramine metabolites M1 and M2. Page: 3.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. | 1996 Nov |
|
Sibutramine: a review of the pharmacology of a novel anti-obesity agent. | 1997 Mar |
|
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. | 1998 Aug |
|
Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. | 1999 Sep |
|
[Obesity: principles of drug therapy]. | 2000 Aug |
|
An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. | 2000 Oct |
|
Sibutramine in overweight/obese hypertensive patients. | 2001 Dec |
|
Organic hypomania secondary to sibutramine-citalopram interaction. | 2002 Feb |
|
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. | 2002 Jan |
|
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. | 2002 Sep |
|
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. | 2003 Dec |
|
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. | 2003 Sep |
|
[Pharmacotherapy of obesity]. | 2004 Oct 7 |
|
Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. | 2006 May |
|
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. | 2007 Apr 17 |
|
Open channel block of A-type, kv4.3, and delayed rectifier K+ channels, Kv1.3 and Kv3.1, by sibutramine. | 2007 May |
|
Myocardial infarction induced by appetite suppressants in Malaysia. | 2007 Nov 1 |
|
The endocannabinoid system as a target for obesity treatment. | 2008 |
|
[Pharmacological therapy of obesity]. | 2008 Apr |
|
Sibutramine: current status as an anti-obesity drug and its future perspectives. | 2008 Aug |
|
Sibutramine-induced acute myocardial infarction in a young lady. | 2008 Nov |
|
The use of sibutramine in the management of obesity and related disorders: an update. | 2009 |
|
Long-term effects of weight-reducing drugs in hypertensive patients. | 2009 Jul 8 |
|
Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. | 2009 Sep |
|
Oleanolic acid, a natural triterpenoid improves blood glucose tolerance in normal mice and ameliorates visceral obesity in mice fed a high-fat diet. | 2010 Apr 15 |
|
Diabesity: therapeutic options. | 2010 Jun |
|
[32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine]. | 2010 May |
|
Elevation of QT dispersion after obesity drug sibutramine. | 2010 Nov |
|
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. | 2011 Feb 21 |
|
Effects of oral anorexiant sibutramine on the expression of cytochromes P450s in human hepatocytes and cancer cell lines. | 2013 Dec |
|
Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes. | 2013 Sep 5 |
|
Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment. | 2015 Nov |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:45:33 GMT 2023
by
admin
on
Sat Dec 16 17:45:33 GMT 2023
|
Record UNII |
WV5EC51866
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175372
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
NDF-RT |
N0000175372
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
WHO-ATC |
A08AA10
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
NDF-RT |
N0000175424
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
DEA NO. |
1675
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
WHO-VATC |
QA08AA10
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
NDF-RT |
N0000000102
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
NDF-RT |
N0000000114
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
NDF-RT |
N0000000109
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
||
|
LIVERTOX |
NBK548248
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
36514
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1419
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
SIBUTRAMINE
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
2586
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
WV5EC51866
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
5210
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
100000084327
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
SUB10512MIG
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
DB01105
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
6124
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
C75965
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
C058254
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
2440
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
106650-56-0
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
Sibutramine
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
DTXSID1023578
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
7209
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | |||
|
m9894
Created by
admin on Sat Dec 16 17:45:35 GMT 2023 , Edited by admin on Sat Dec 16 17:45:35 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
BINDER->LIGAND |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |